Donepezil in the treatment of dementia with Lewy bodies [1]

American Journal of Geriatric Psychiatry

Volumn 12, Issue 5, 2004, Pages 542-544

  Beversdorf, David Q ^a   Warner, Jennifer L ^a   Davis, Rebecca A ^a   Sharma, Umesh K ^a   Nagaraja, Haikady N ^a   Scharre, Douglas W ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; PLACEBO; RIVASTIGMINE;

AGED; CLINICAL TRIAL; COGNITION; DEMENTIA; DOPAMINERGIC SYSTEM; FEMALE; FUNCTIONAL ASSESSMENT; HALLUCINATION; HUMAN; LETTER; LEWY BODY; MALE; RATING SCALE; RECALL; TREATMENT OUTCOME;

EID: 84903195688     PISSN: 10647481     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019442-200409000-00016     Document Type: Letter

References (5)

1. Mega MS, Masterman DL, Benson DF, et al: Dementia with Lewy bodies: reliability and validity of clinical and pathological criteria. Neurology 1996; 47:1403-1409
2. Perry EK, Haroutunian V, Davis KL, et al: Neocortical cholinergic activities differentiate Lewy-body dementia from classical Alzheimer's disease. NeuroReport 1994; 5:747-749
3. McKeith I, del Ser T, Spano P, et al: Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study. Lancet 2000; 356:2031-2036
4. McKeith IG, Galasko D, Kosaka K, et al: Consensus Guidelines for the Clinical and Pathological Diagnosis of Dementia With Lewy Bodies: A Report of the CDLB International Workshop. Neurology 1996; 47:1113-1124
5. Sarter M, Bruno JP: Cognitive functions of cortical acetylcholine: toward a unifying hypothesis. Brain Res Rev 1997; 23:28-46